Mylan's Generic Oracea Infringes Galderma IP: Judge

Law360, New York (August 26, 2011, 7:47 PM EDT) -- A Delaware federal judge on Friday found that Mylan Pharmaceuticals Inc.'s efforts to bring a generic version of the rosacea drug Oracea to the market infringed a valid patent held by Galderma Laboratories Inc.

Following a bench trial, U.S. District Judge Leonard P. Stark determined that one of the five patents asserted by Galderma in a bid to keep Mylan from launching its proposed generic product was both valid and infringed by the patent. The judge also ruled that two of the patents were valid but...
To view the full article, register now.